ClinicalTrials.gg
RecruitingNCT06703073Updated Jul 31, 2026

JUST BREATHE, Breathing Life Into Innovative Therapies for ARDS (Master Record)

A Phase 2 interventional study of Cohort A: vilobelimab and Cohort A: placebo in Acute Respiratory Distress Syndrome (ARDS), ARDS and ARDS (Acute Respiratory Distress Syndrome), sponsored by PPD Development, LP. Recruiting at 41 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by PPD Development, LP · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 324 studies in Respiratory Distress Syndrome with a site in United States — 46 open to participants now, 56 under way, 7 of them phase 3. Respiratory Distress Syndrome · United States.

Planned enrollment
19th of 250
600 · median 52
Started
2025
with 13 others
Phase 2
74 of 324
8 open now
Primary completion
2028-07
later than 35 of 55 live
Registered
300th of 324
by date

Among the 324 studies in Respiratory Distress Syndrome with a site in United States, this one is the 19th largest by planned enrollment of the 250 interventional ones that give a count, is one of 14 that started in 2025, is one of 74 in phase 2, reaches primary completion later than 35 of the 55 other live ones, and was the 300th registered.

Respiratory Distress Syndrome

1,387 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.

Browse Respiratory Distress Syndrome studies →

Open to participants now

46 of the 324 studies in Respiratory Distress Syndrome with a site in United States are open now. Recruiting first, the newest first:

40 more — sign in →

All 46 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 193 Respiratory Distress Syndrome studies recruiting now, 117 (61%) set no upper age limit and 48 (25%) stop at 75 or younger; 50 take children under 18; 9 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 324 studies in Respiratory Distress Syndrome with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2 multicenter, randomized, double-blinded, placebo-controlled study that will evaluate the safety and efficacy of host-directed therapeutics in hospitalized adults diagnosed with Acute Respiratory Distress Syndrome (ARDS) utilizing a platform trial design. Participants will be randomized to receive either a placebo or one of the active treatments.

This record describes the default procedures and analyses for all cohorts. Each specific cohort may have additional eligibility requirements, safety and efficacy procedures, or endpoints, which will be described in the corresponding intervention-specific records on clinicaltrials.gov listed below in the detailed description.

Read the detailed description

This is a master protocol for a Phase 2 platform clinical trial to evaluate host-directed therapeutic candidates (i.e., investigational product, IP) for the treatment of hospitalized participants diagnosed with ARDS. The safety and efficacy of each IP will be studied within its own cohort (IP versus Placebo). All patients will continue to receive standard treatments for ARDS as per the investigator. An individual participant will complete the study in approximately 90 days. The study will include a screening period (\<24 hours from providing informed consent to treatment), in-hospital treatment period with IP/placebo starting on Day 1 through discharge from the hospital, and a follow-up period after discharge from the hospital through the end of study (Day 90 + 2 weeks).

Outcome data will be assembled for each patient over time (such as ventilatory status, oxygenation, and survival). Functional status using the WHO Ordinal scale and Karnofsky scale will be collected. Resource utilization will be calculated (length of stay in a critical care setting, days intubated, and survival).

All participants will undergo a series of physical exams, laboratory assessments/biomarker collections, ECG, Chest X-ray or CT scan, and questionnaires through Day 90. Exploratory biomarkers will be evaluated over time to facilitate clinical learning.

For information specific to each intervention included in this platform trial, please refer to the below corresponding, separate, clinicaltrials.gov records:

Vilobelimab NCT06701682 ; Paridiprubart NCT06701669 ; Bevacizumab NCT06701656

03

Conditions studied

  • Acute Respiratory Distress Syndrome (ARDS)
  • ARDS
  • ARDS (Acute Respiratory Distress Syndrome)
  • Acute Respiratory Distress Syndrome

Keywords

  • BARDA
  • JUST BREATHE
  • ARDS
  • Acute Respiratory Distress Syndrome
  • Acute Respiratory Failure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Each participant must meet all of the following criteria to be enrolled in this study:

  • Participant (or their Legally Authorized Representative (LAR)) provides and agrees to comply with protocol requirements
  • Participant is at least 18 years of age or older at the time of consent.
  • Participant with signs and symptoms of ARDS according to the Berlin definition of ARDS.

Note that participants on noninvasive ventilation may be screened.

  • Participant of must agree to either abstinence or use at least one primary form of , not including hormonal contraception, from the time of screening through Day 28. Additional cohort-specific requirements may apply
  • Participant agrees to not participate in another interventional study while participating in this study (i.e., through Day 90).

Exclusion criteria

Exclusion Criteria

Participants will be excluded from the study if any of the following apply:

  • Participant with ARDS or at risk of developing ARDS due to the following reasons: trauma, large volume aspiration, or transfusion.
  • Participant with pulmonary edema due to cardiogenic pulmonary edema/fluid overload or hypoxemia primarily attributable atelectasis, in the absence of a predisposing risk factor for ARDS.
  • Participant who demonstrates an improvement in oxygenation and ventilatory support 24 hours prior to or during screening up to randomization, such that per investigator clinical judgement, the participant is expected to have significant improvement in lung function over subsequent 24 hours regardless of additional interventions.
  • Participant is known to be pregnant, nursing, or with a positive (urine and/or serum test) pregnancy test.
  • Participant is anticipated to be transferred to another hospital which is not a study site within 72 hours.
  • Participant is not expected to survive for 72 hours.
  • Participant has been on invasive mechanical ventilation or ECMO for ARDS for more than 48 hours for ARDS at the time of consent.
  • Participant has an underlying clinical condition where, in the opinion of the Investigator and based on their clinical judgement, it would be extremely unlikely that the participant would come off ventilation
  • Participant has severe requiring continuous long-term home oxygen therapy or mechanical ventilation (noninvasive ventilation or via tracheotomy) except for CPAP or bi-level positive airway pressure used solely for sleep-disordered breathing.
  • Participant has interstitial lung disease or idiopathic pulmonary fibrosis requiring continuous chronic home oxygen therapy.
  • Participant has NY Heart Association Class IV congestive heart failure.
  • Participant has a known allergy to any study medication or any of its .
  • Participant is receiving systemic therapy for solid organ or hematopoietic cancer or transplant anti-rejection medication therapy OR systemic immunosuppressive (prednisone ≥20 mg daily or equivalent). NOTE: Patients onreceiving chronic low dose immunosuppressive therapy may be enrolled(e.g., prednisone \<20 mg/day or equivalent) and patients on stable, long-term maintenance immunosuppression (e.g., tacrolimus, mycophenolate, orsirolimus) and patients receiving physiologic replacement and hormonal therapies for breast cancer (e.g., tamoxifen, letrozole) or prostate cancer (leuprolide, bicalutamide) for >60 days may be eligible at the investigator's discretion of the investigator in consultation with the medical monitor.
  • Participant is receiving ongoing cytotoxic chemotherapy (IV or oral), OR combination targeted/immunotherapy regimens for cancer within the past 60 days. Note: Participants receiving non-myelosuppressive cancer therapy (e.g., hormonal therapy or selected targeted / immunotherapy regimens) may be eligible if therapy has been stable ≥60 days; The use of hydroxyurea to manage patients with chronic myeloid leukemia, polycythemia vera, essential thrombocythemia or sickle cell disease is permitted.
  • Participant received treatment with an immunomodulator or immunosuppressant drugs within 5 half-lives or 30 days (whichever is longer) before randomization.
  • Participant with concurrent infections or history of the following:

    1. Known active tuberculosis,
    2. Known active , or
    3. and a less than 50 or a detectable viral load of >200 copies/mL HIV RNA.
  • Participant received treatment with any other investigational drugs within 30 days prior to consent.
  • Participant had a history of abdominal fistula, gastrointestinal perforation, intra-abdominal abscess within 28 days of screening or inadequate wound healing secondary to major thoracoabdominal surgery at the time of screening.
  • Participant is considered by the investigator, for any reason, to be an unsuitable candidate for the study.

Participant may have additional cohort-specific requirements.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
600 participants (estimated)

Study arms

  • Experimental
    Cohort A: vilobelimab

    Drug: Cohort A: vilobelimab

  • Placebo comparator
    Cohort A: placebo

    Drug: Cohort A: placebo

  • Experimental
    Cohort B: paridiprubart

    Drug: Cohort B: paridiprubart

  • Placebo comparator
    Cohort B: placebo

    Drug: Cohort B: placebo

  • Experimental
    Cohort C: bevacizumab

    Drug: Cohort C: bevacizumab

  • Placebo comparator
    Cohort C: placebo

    Drug: Cohort C: placebo

Interventions

  • Administered as an IV formulation of 800 mg per dose and up to 6 doses (planned for Days 1, 2, 4, 8, 15, and 22, if participant is in hospital setting and deemed appropriate by the investigator)

  • DrugCohort A: placebo

    Administered as an IV formulation of placebo of up to 6 doses (planned for Days 1, 2, 4, 8, 15, and 22, if participant is in hospital setting and deemed appropriate by the investigator)

  • Administered as a single IV dose of 15 mg/kg up to maximum of 1440 mg on Day 1

  • DrugCohort B: placebo

    Administered as a single IV dose of placebo on Day 1

  • Administered as a single IV dose of 500 mg on Day 1

  • DrugCohort C: placebo

    Administered as a single IV dose of placebo on Day 1

06

What researchers measure

Primary outcomes

  1. All-cause mortality (ACM) rate at Day 28

    Time frame: Day 28

Secondary outcomes

  1. ACM at Day 60 and Day 90

    Time frame: Day 60 and Day 90

  2. ACM+ at Day 28, Day 60, and Day 90

    Note: ACM+ composite score will be constructed by combining ACM and participant-relevant, infection-related Adverse Events (AE) and Serious Adverse Events (SAEs) from the MedDRA toxic/septic shock standardized MedDRA queries (SMQ).

    Time frame: Day 28, Day 60, and Day 90

  3. Improvements in oxygenation measured as change from baseline in PaO2/FiO2 ratio up to and including Day 28 (or discharge, whichever is earlier)

    Time frame: Up to and including Day 28 or until Discharge (whichever is earlier)

  4. Incidence of new invasive mechanical ventilation use during the study up to and including Day 28

    Time frame: Up to and including Day 28

  5. Ventilator-free days up to and including Day 28

    Time frame: Up to and including Day 28

  6. Proportion of participants alive and free of mechanical ventilation at Days 28, 60, and 90

    Time frame: Days 28, 60, and 90

  7. Time to recover gas exchange to a PaO2/FiO2 ≥ 300 measured on 2 consecutive days during the first 28 days after informed consent

    Time frame: Up to and including Day 28

  8. Extracorporeal Membrane Oxygenation (ECMO) free days up to and including Day 28

    Time frame: up to and including Day 28

  9. Incidence of participants with new ECMO use during the study up to and including Day 28.

    Time frame: up to and including Day 28

  10. Proportion of participants alive and free of ECMO at Days 28, 60, and 90

    Time frame: Days 28, 60, and 90.

  11. Proportion of participants achieving a ≥2-point improvement from baseline in the World Health Organization (WHO) 8-levels ordinal scale (from 0-8)

    Time frame: While Hospitalized (up to 90 days)

  12. Time to an improvement of one category and two categories from baseline using the WHO 8-levels ordinal scale (from 0-8) at Days 28, 60, and 90 (while hospitalized)

    Time frame: While Hospitalized (up to 90 days)

  13. Mean change in the WHO 8-levels ordinal scale from baseline through Day 90 (while hospitalized)

    Time frame: While Hospitalized (up to 90 days)

  14. Proportion of participants who improve clinical status as measured by the Karnofsky scale

    The Karnofsky scale is used to assess the general condition of the patient. Scores range from 0 to 100 with higher scores indicating better functional ability.

    Time frame: Post hospitalization through Day 90

  15. Days of hospitalization up to and including Day 28

    Time frame: up to and including Day 28

  16. Days of ICU stay up to and including Day 28

    Time frame: up to and including Day 28

  17. Change in Short Form Health Survey (SF-12) from hospital discharge to Day 60 and to Day 90

    The SF-12 is a self-reported outcome measure composed by 12 items which examine eight dimensions of physical and mental health. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning.

    Time frame: From hospital discharge to Day 60 and to Day 90

  18. Change in St. George's Respiratory Questionnaire (SGRQ) from hospital discharge to Day 60 and to Day 90

    The SGRQ comprises of 50 items and consists of two parts. The first part pertains to symptoms and the second pertains to functional status as well as social and psychological impact of disease. Overall scores range between 0 and 100 with higher scores indicating more limitations.

    Time frame: From hospital discharge to Day 60 and to Day 90

  19. Incidence and severity of adverse events (AEs) /adverse event of special interest (AESI) / serious adverse event (SAEs)

    Time frame: Through Day 90

07

Study locations

27 of 41 sites recruiting
08

References and documents

Publications

  • Truwit JD, Fleming K, Nanchal RS. Empowering Respiratory Therapists to Restrict Nebulized 3% Saline and N-Acetylcysteine During Mechanical Ventilation. Respir Care. 2025 Aug;70(8):937-945. doi: 10.1089/respcare.12586. Epub 2025 Feb 24. PubMed 40028879 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jul 2028, 37 months after the start.

Of 59 phase 2 interventional studies under Respiratory Distress Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's planned 37 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2024
First posted
Nov 25, 2024
StartActual
Jun 10, 2025
Primary completionEst.
Jul 2028
CompletionEst.
Sep 2028
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06703073
Lead sponsor
PPD Development, LP
Collaborators
Biomedical Advanced Research and Development Authority, InflaRx GmbH, Edesa Biotech Inc., Genentech, Inc.
Responsible party
Sponsor
First posted
Nov 25, 2024
Start date
Jun 10, 2025
Primary completion
Jul 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Jul 31, 2026

Study contacts

Just Breathe Trial Team
Contact
crgjustbreathealerts.sm@thermofisher.com
Please email

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vilobelimab · NI-0101 · Bevacizumab

Start the discussion